Since COX-2 is under the control of both NF-κB and ATF2, inhibition of NF-κB (with, e.g., Bay 11-7085) and also p38α (with, e.g., PD169316, SB202190, or SB203580, Table 1) indeed reduced COX-2 protein levels and increased the responsiveness to PDT in human ovarian (HeLa) and bladder cancer (T24) cells as well as radiation-induced mouse fibrosarcoma (RIF-1) cells [202, 239, 244]. The gene discussed is NFKB1; the disease is urinary bladder cancer.